Starpharma P / E
Was ist das P / E von Starpharma?
P / E von Starpharma Holdings Limited ist N/A
Was ist die Definition von P / E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P / E von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Starpharma
Was macht Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Unternehmen mit p / e ähnlich Starpharma
- Equitorial Exploration hat P / E von N/A
- Quinto Resources hat P / E von N/A
- Melior Resources hat P / E von N/A
- Anevia SA hat P / E von N/A
- New Found Gold Corp hat P / E von N/A
- Bank of Marin Bancorp hat P / E von N/A
- Starpharma hat P / E von N/A
- National Oxygen hat P / E von N/A
- PZ Cussons Plc hat P / E von N/A
- PowerFleet Inc hat P / E von N/A
- Edvance International hat P / E von N/A
- First Vanadium hat P / E von N/A
- AltiGen Communications hat P / E von N/A